Exegiline Pharma is developing a novel multifunctional oral drug, MT-031, for the treatment of dementia and Alzheimer's disease. MT-031's structure combines rivastigmine (Exelon) and rasagiline (Azilect) moieties and has the beneficial properties of both and more. It works as a dual acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) inhibitor as well a selective irreversible inhibition of MAO-A.
MT-031 has a brain-permeable novel multifunctional MAO-AChE/BuChe inhibitor, anti-inflammatory properties, neuroprotective activity, and cognitive- and memory-enhancing activities.
The molecule and its indications are protected by US and European patents.
The company was established at Youdim Pharmaceuticals, a pharmaceutical company and incubator.
Cumulative Funding Raised Over Time ($)
Employees Over Time
Exegiline Pharma Climate Tech relevance
null
Latest News
No Data, yet.
Sorry, no content found under this section.
Apr 22, 2022
www.jpost.com
In Parkinson's Awareness Month, Parkinson's pioneer wins Israel Prize